An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. Eur Urol. 2019 01; 75(1):201-203.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Humans
Lung Neoplasms
Male
Neoplasms, Germ Cell and Embryonal
Seminoma
Testicular Neoplasms
Treatment Failure

authors with profiles

Jonathan Chung